

Network Systems  
Science & Advanced  
Computing  
  
Biocomplexity Institute  
& Initiative  
  
University of Virginia

# Estimation of COVID-19 Impact in Virginia

December 22<sup>nd</sup>, 2020

(data current to December 19<sup>th</sup> – 21<sup>st</sup>)

Biocomplexity Institute Technical report: TR 2020-161



---

**BIOCOMPLEXITY INSTITUTE**

[biocomplexity.virginia.edu](http://biocomplexity.virginia.edu)

# About Us

- Biocomplexity Institute at the University of Virginia
  - Using big data and simulations to understand massively interactive systems and solve societal problems
- Over 20 years of crafting and analyzing infectious disease models
  - Pandemic response for Influenza, Ebola, Zika, and others



## Points of Contact

Bryan Lewis  
[brylew@virginia.edu](mailto:brylew@virginia.edu)

Srini Venkatramanan  
[srini@virginia.edu](mailto:srini@virginia.edu)

Madhav Marathe  
[marathe@virginia.edu](mailto:marathe@virginia.edu)

Chris Barrett  
[ChrisBarrett@virginia.edu](mailto:ChrisBarrett@virginia.edu)

## Biocomplexity COVID-19 Response Team

Aniruddha Adiga, Abhijin Adiga, Hannah Baek, Chris Barrett, Golda Barrow, Richard Beckman, Parantapa Bhattacharya, Andrei Bura, Jiangzhuo Chen, Clark Cucinell, Patrick Corbett, Allan Dickerman, Stephen Eubank, Arindam Fadikar, Joshua Goldstein, Stefan Hoops, Ben Hurt, Sallie Keller, Ron Kenyon, Brian Klahn, Gizem Korkmaz, Vicki Lancaster, Bryan Lewis, Dustin Machi, Chunhong Mao, Achla Marathe, Madhav Marathe, Fanchao Meng, Henning Mortveit, Mark Orr, Joseph Outten, Akhil Peddireddy, Przemyslaw Porebski, SS Ravi, Erin Raymond, Jose Bayoan Santiago Calderon, James Schlitt, Aaron Schroeder, Stephanie Shipp, Samarth Swarup, Alex Telionis, Srinivasan Venkatramanan, Anil Vullikanti, James Walke, Amanda Wilson, Dawen Xie



# Overview

- **Goal:** Understand impact of COVID-19 mitigations in Virginia
- **Approach:**
  - Calibrate explanatory mechanistic model to observed cases
  - Project infections for next 4 months
  - Consider a range of possible mitigation effects in "what-if" scenarios
- **Outcomes:**
  - Ill, Confirmed, Hospitalized, ICU, Ventilated, Death
  - Geographic spread over time, case counts, healthcare burdens

# Key Takeaways

Projecting future cases precisely is impossible and unnecessary.

Even without perfect projections, we can confidently draw conclusions:

- **Case rate growth in Virginia slows and steadies with mixed patterns across commonwealth**
- VA mean weekly incidence (43/100K) steady (from 44) as national surge slows and is slightly down for first week in months (to 59/100K from 66/100K).
- Recent updates:
  - Preliminary estimates for vaccination impact
  - Planning scenarios remain on Christmas holiday, starting Dec 24<sup>th</sup>
- Behavioral changes can outpace impact of optimistic vaccine rollout and prevent significantly more cases by Spring
- The situation is changing rapidly. Models will be updated regularly.



# Situation Assessment

---



UNIVERSITY OF VIRGINIA


---

BIOCOMPLEXITY INSTITUTE

# Case Rate (per 100k) by VDH District

## Surging Rates continue



- Majority of districts have increasing rates
- Many districts experiencing highest rates of pandemic
- Some districts remain steady or decreasing



# Test Positivity by VDH District

## Weekly changes in test positivity by district

- Increasing levels in many districts throughout the commonwealth with many districts above 10% for several weeks
- 101 counties reporting over 10% on Dec 9




## County level test positivity rates for RT-PCR tests.

**Green:** Test positivity <5.0%  
(or with <20 tests in past 14 days)

**Yellow:** Test positivity 5.0%-10.0% (or with <500 tests and <2000 tests/100k and >10% positivity over 14 days)

**Red:** >10.0% and not meeting the criteria for "Green" or "Yellow"




# District Trajectories

**Goal:** Define epochs of a Health District's COVID-19 incidence to characterize the current trajectory

**Method:** Find recent peak and use hockey stick fit to find inflection point afterwards, then use this period's slope to define the trajectory

Hockey stick fit




Trajectory	Description	Weekly Case Rate (per 100K) bounds	# Districts (prev week)
Declining	Sustained decreases following a recent peak	below -0.9	12 (2)
Plateau	Steady level with minimal trend up or down	above -0.9 and below 0.5	3 (1)
Slow Growth	Sustained growth not rapid enough to be considered a Surge	above 0.5 and below 2.5	11 (7)
In Surge	Currently experiencing sustained rapid and significant growth	2.5 or greater	9 (25)



# District Trajectories

Status	# Districts (prev week)
Declining	12 (2)
Plateau	3 (1)
Slow Growth	11 (7)
In Surge	9 (25)

Curve shows smoothed case rate (per 100K)  
 Trajectories of states in label & chart box  
 Case Rate curve colored by Reproductive



# Estimating Daily Reproductive Number



Dec 20<sup>th</sup> Estimates

Region	Date Confirmed R <sub>e</sub>	Date Confirmed Diff Last Week
State-wide	0.924	-0.470
Central	0.918	-0.214
Eastern	1.139	-0.248
Far SW	0.945	-0.258
Near SW	0.848	-0.537
Northern	0.821	-0.436
Northwest	0.972	-0.250

## Methodology


- Wallinga-Teunis method (EpiEstim<sup>1</sup>) for cases by confirmation date
- Serial interval: 6 days (2 day std dev)
- Using Confirmation date since due to increasingly unstable estimates from onset date due to backfill

1. Anne Cori, Neil M. Ferguson, Christophe Fraser, Simon Cauchemez. A New Framework and Software to Estimate Time-Varying Reproduction Numbers During Epidemics. American Journal of Epidemiology, Volume 178, Issue 9, 1 November 2013, Pages 1505–1512, <https://doi.org/10.1093/aje/kwt133>




# Changes in Case Detection


Timeframe (weeks)	Mean days	% difference from overall mean
April (13-16)	8.3	51%
May (17-21)	5.6	2%
June (22-25)	5.9	7%
July (26-30)	6.4	16%
Aug (31-34)	4.8	-12%
Sept (35-38)	4.4	-20%
Oct (39-43)	4.3	-21%
Nov (44-47)	4.4	-21%
Overall (13-47)	5.5	0%




## Test positivity vs. Onset to Diagnosis



## Days from Onset to Diagnosis and Test Positivity - Weekly




# Mask usage in Virginia




State level mask usage as reported via Facebook surveys over the past month shows ranges from 83% to 91%

- Relatively stable over time
- Limited variance across the commonwealth
- ~3000 daily responses from VA

Data Source: <https://covidcast.cmu.edu>



Some county level fluctuations since beginning of Sept., though data quality may be affected by sample sizes.



Correlations seen among VA counties between mask use and case rate are now stronger due to surging growth



Slope: - 2.85; for every % we see a ~3/100K case rate difference

# Health Care Worker Prevalence (per 100K)

## Case Rates among health workers

- Based on census counts of patient-facing health care workers (Practitioners and Technologists)
- Prevalence rate for week ending Dec 19
- Many areas have high burden on HCW, especially southern VA




HCW Point Prevalence by Zip Code  
(2020-12-19)




# Race and Ethnicity – Recent Rate Changes (per 100K)

## Recent Changes in Race and Ethnicity Rates (per 100k)

- Two week change in population level rates
- Black, Latinx and 2 or more races populations have much higher changes in rates; disparity is more pronounced in some districts than others
- Based on 2019 census race-ethnicity data by county




# Race and Ethnicity cases per 100K



## Rates per 100K of each Racial-Ethnic population by Health District


- Each Health District's Racial-Ethnic population is plotted by their Hospitalization and Case Rate
- Points are sized based on their overall population size
- Overlapping labels removed for clarity

# Impact across Density and Income



All zip codes show similar slowing of growth, wealthiest zip codes drop the fastest.


VDH mean cases per 100k by zip code population density (person/ sq mile)  
and average household income (dollars/ household years) quantiles  
07/18/20 - 07/24/20



Full evolution of pandemic, shows shifts from denser and wealthier zip codes to poorer and less dense zip codes, followed by a repeat of the pattern. Recently see an uptick across the spectrum of density and income.


# Other State Comparisons

## Trajectories of States



- Many of the states with huge surges in past 6 weeks (Plains & Midwest) are subsiding

## Virginia and her neighbors



- VA slows its growth
- Many mid-Atlantic states remain in surge (20 total in US)
- Several neighbors have plateaued, though rates remain high
- All states have highest rates of the pandemic in past 2 weeks

# Zip code level weekly Case Rate (per 100K)

## Case Rates in the last week by zip code



- Concentrations of very high prevalence in many zip codes
- Several of the top ten zip codes are home to prisons
- Southwest has considerable concentration of high prevalence zips
- Some counts are low and suppressed to protect anonymity, those are shown in white

Rank	Zip Code Name	Prevalence
1	24430 Craigsville *	24,670
2	24635 Pocahontas *	18,880
3	22729 Mitchells *	7,510
4	23922 Burkeville *	5,410
5	23109 Mathews	4,410
6	24315 Bland *	4,150
7	22850 Singers Glen	4,040
8	24260 Honaker	3,900
9	23936 Dillwyn *	3,380
10	24225 Cleveland	3,010

Only includes zips with pop  $\geq 1000$  and no supp. data.

\* Denotes zip codes with state prisons.

Point Prevalence by Zip Code  
(2020-12-19)



UNIVERSITY OF VIRGINIA

BIOCOMPLEXITY INSTITUTE

# Risk of Exposure by Group Size

**Case Prevalence in the last week by zip code used to calculate risk of encountering someone infected in a gathering of randomly selected people (group size 25)**


- Assumes 3 undetected infections per confirmed case (ascertainment rate from recent seroprevalence survey)
- On left, minimum size of a group with a 50% chance an individual is infected by zip code (eg in a group of 20 in Staunton, there is a 50% chance someone will be infected)
- Some zip codes have high likelihood of exposure even in groups of 25

Rank	Zip Code Name	Group Size
1	24430 Craigsville *	2
2	24635 Pocahontas *	3
3	22729 Mitchells *	9
4	23922 Burkeville *	12
5	23109 Mathews	15
6	24315 Bland *	16
7	22850 Singers Glen	17
8	24260 Honaker	17
9	23936 Dillwyn *	20
10	24225 Cleveland	23

Only includes zips with pop  $\geq 1000$  and no supp. data.

\* Denotes zip codes with state prisons.

Group Size Needed for 50% Likelihood of  $\geq 1$  Infected




Group Size	Rank	Zip Code Name	Likelihood
High : 300+	1	24430 Craigsville *	>99%
260	2	24635 Pocahontas *	99%
220	3	22729 Mitchells *	86%
180	4	23922 Burkeville *	75%
140	5	23109 Mathews	68%
100	6	24315 Bland *	65%
60	7	22850 Singers Glen	64%
Low : 20	8	24260 Honaker	63%
Nan	9	23936 Dillwyn *	58%
	10	24225 Cleveland	53%

Only includes zips with pop  $\geq 1000$  and no supp. data.

\* Denotes zip codes with state prisons.


Likelihood of  $\geq 1$  Infected Members (Group of 25)



# New variant of SARS-CoV2 circulating in UK

**Prevalence in the UK of variant with potentially increased transmissibility but no evidence of higher severity**

- Aliases: [Variant VUI 202012/01](#) and [Lineage B.1.1.7](#)
- No direct evidence of this variant in US yet, but recent genomic surveillance in US is limited, it is likely circulating
- This variant is still detected by PCR and is unlikely to alter efficacy of vaccines or other immune treatments
- Evolution expected when virus under selective pressure
- NERVTAG suggests that “[VUI-202012/01 demonstrates a substantial increase in transmissibility compared to other variants](#)”
- Mutations include but not limited to
  - (69 Y-) [Two deletions in the spike protein associated with immune evasion](#); (N501Y) [Mutation in the receptor binding domain w/ higher binding affinity w/ ACE2](#); (P681H) [Mutation in the S1/S2 furin cleavage site which promotes entry](#)



[nextstrain.org](https://nextstrain.org)

# Model Update – Adaptive Fitting

---



# Adaptive Fitting Approach

**Each county fit precisely, with recent trends used for future projection**



- Allows history to be precisely captured, and used to guide bounds on projections

**Model:** An alternative use of the same meta-population model, PatchSim

- Allows for future “what-if” Scenarios to be layered on top of calibrated model
- Eliminates connectivity between patches, to allow calibration to capture the increasingly unsynchronized epidemic

**External Seeding:** Steady low-level importation


- Widespread pandemic eliminates sensitivity to initial conditions
- Uses steady 1 case per 10M population per day external seeding



# Using Ensemble Model to Guide Projections

An ensemble methodology that combines the Adaptive Fitting and machine learning and statistical models has been developed and refined

- **Models:** Adaptive Fitting, ARIMA, LSTM, AR, spatially driven AR, Kalman Filters (ENKF)
- This approach facilitates the use of other data streams (weather, mobility, etc.)
- Ensemble provides scaffolding for the Adaptive Fitting's short-term projections




# Seroprevalence updates to model design

**Several seroprevalence studies provide better picture of how many actual infections have occurred**

- Virginia Serology Study estimated 2.4% of Virginians estimated infected (as of Aug 15<sup>th</sup>)
- CDC Nationwide Commercial Laboratory Seroprevalence Survey estimated 4.1% [2.4% – 6.2%] seroprevalence as of Oct 9<sup>th</sup>-21<sup>st</sup> up from 3.2% a month earlier

**These findings are equivalent to an ascertainment ratio of ~3x, with bounds of (1x to 7x)**

- Thus for 3x there are 3 total infections in the population for every confirmed case
- Uncertainty design has been shifted to these bounds (previously higher ascensions as was consistent earlier in the pandemic were being used)



<https://covid.cdc.gov/covid-data-tracker/#national-lab>

## Virginia Coronavirus Serology Project Interim findings by region and statewide - July 22, 2020

Region	Number of participants	Number antibody positive	Crude prevalence per 100 participants	Weighted prevalence* per 100 population (95% CI)
Central	400	8	2.0	3.0 (0.5, 5.5)
East	707	9	1.3	1.5 (-0.2, 3.2)
Northern	819	36	4.4	4.2 (2.5, 5.9)
Northwest	756	11	1.5	0.9 (0.2, 1.6)
Southwest	431	3	0.7	1.0 (-0.2, 2.1)
Virginia	3,113	67	2.2	2.4 (1.6, 3.1)

\* Weighted prevalence is reweighted by region, age, sex, race, ethnicity, and insurance status to match census population.

<https://www.vdh.virginia.gov/content/uploads/sites/8/2020/08/VDH-Serology-Projects-Update-8-13-2020.pdf>

# Calibration Approach

- **Data:**
  - County level case counts by date of onset (from VDH)
  - Confirmed cases for model fitting
- **Calibration:** fit model to observed data and ensemble's forecast
  - Tune transmissibility across ranges of:
    - Duration of incubation (5-9 days), infectiousness (3-7 days)
    - Undocumented case rate (1x to 7x) guided by seroprevalence studies
    - Detection delay: exposure to confirmation (4-12 days)
  - Approach captures uncertainty, but allows model to precisely track the full trajectory of the outbreak
- **Project:** future cases and outcomes generated using the collection of fit models run into the future
  - **Mean trend from last 14 days of observed cases and first week of ensemble's forecast used**
  - Outliers removed based on variances in the previous 3 weeks
  - 2 week interpolation to smooth transitions in rapidly changing trajectories

## COVID-19 in Virginia:

Dashboard Updated: 12/22/2020  
Data entered by 5:00 PM the prior day.

Cases, Hospitalizations and Deaths					
Total Cases*			Total Hospitalizations**	Total Deaths	
<b>314,481</b>			<b>17,083</b>	<b>4,705</b>	
(New Cases: 3,591)^	Confirmed†	Probable†	Confirmed†	Probable†	Confirmed†
268,472	46,009	16,563	520	4,221	484

\* Includes both people with a positive test (Confirmed), and symptomatic with a known exposure to COVID-19 (Probable).  
\*\* Hospitalization status at time case was investigated by VDH. This underrepresents the total number of hospitalizations in Virginia.  
^New cases represent the number of confirmed and probable cases reported to VDH in the past 24 hours.  
† VDH adopted the updated CDC COVID-19 confirmed and probable surveillance case definitions on August 27, 2020. Found here: <https://www.cdc.gov/nndss/conditions/coronavirus-disease-2019-covid-19/case-definition/2020/08/05/>  
Source: Cases - Virginia Electronic Disease Surveillance System (VEDSS), data entered by 5:00 PM the prior day.

Outbreaks	
Total Outbreaks*	Outbreak Associated Cases
<b>1,836</b>	<b>41,727</b>

\* At least two (2) lab confirmed cases are required to classify an outbreak.

Testing (PCR Only)	
Testing Encounters PCR Only*	Current 7-Day Positivity Rate PCR Only**
<b>3,993,232</b>	<b>11.4%</b>

\* PCR" refers to "Reverse transcriptase polymerase chain reaction laboratory testing."  
\*\* Lab reports may not have been received yet. Percent positivity is not calculated for days with incomplete data.

Multisystem Inflammatory Syndrome in Children	
Total Cases*	Total Deaths
<b>12</b>	<b>0</b>

\*Cases defined by CDC HAN case definition: <https://emergency.cdc.gov/han/2020/han00432.asp>

Accessed 10:00am December 22, 2020

<https://www.vdh.virginia.gov/coronavirus/>

# Scenarios – Seasonal Effects and Vaccines

- Societal changes in the past month have led to an increase in transmission rates, these could continue to drive transmission
  - Seasonal impact of weather patterns, viral mutations, interactions at places of learning, travel related to holidays and traditional large family gatherings, fatigue with infection control practices
  - Population's behaviors determine the level of control of transmission we can achieve
- Vaccination has started, focus on priority groups may limit population level effects initially, though small impacts may be observed in early February
  - Initial rollout estimated at 12.5M people in US (~330K in VA) in January, then 25M (~660K) per month, assumes limited impact from any vaccinations in December.
  - Assume all available vaccine is administered and has 80% efficacy in 2 weeks (timing more sensitive than max efficacy in early stages)
  - Counterfactuals with no vaccine ("NoVax") are provided for comparison purposes

# Scenarios – Seasonal Effects and Vaccines

- Three behavioral scenarios capture possible trajectories starting Dec 24<sup>th</sup>, 2020
  - **Adaptive:** No change from base projection
  - **Adaptive-MoreControl:** 15% decrease in transmission starting Dec 24<sup>th</sup>, 2020
  - **Adaptive-LessControl:** 15% increase in transmission starting Dec 24<sup>th</sup>, 2020
- Vaccinations are incorporated in “base” projections, counterfactuals without vaccinations provide lower bound on vaccines impact
  - **Adaptive-NoVax:** No change from base projection without vaccine
  - **Adaptive-NoVax-MoreControl:** 15% decrease in transmission starting Dec 24<sup>th</sup>, 2020 without vaccine
  - **Adaptive-NoVax-LessControl:** 15% increase in transmission starting Dec 24<sup>th</sup>, 2020 without vaccine



# Model Results

---





BIOCOMPLEXITY INSTITUTE

# Outcome Projections


## Estimated Hospital Occupancy

### Confirmed cases


Virginia Daily Confirmed - Comparison



### Daily Deaths




### Cumulative Confirmed cases



# District Level Projections: Adaptive

## Adaptive projections by District

- Projections that best fit recent trends
- Daily confirmed cases rate (per 100K) by Region (blue solid) with simulation colored by scenario




UNIVERSITY of VIRGINIA

# District Level Projections: Adaptive-MoreControl

## Adaptive projections by District


- Projections that best fit recent trends
- Daily confirmed cases rate (per 100K) by Region (blue solid) with simulation colored by scenario



# District Level Projections: Adaptive-LessControl

## Adaptive projections by District


- Projections that best fit recent trends
- Daily confirmed cases rate (per 100K) by Region (blue solid) with simulation colored by scenario



# Hospital Demand and Bed Capacity by Region

## Capacities\* by Region – Adaptive-LessControl

COVID-19 capacity ranges from 80% (dots) to 120% (dash) of total beds



Week Ending	Adaptive	Adaptive-LessControl
12/20/20	25,271	25,275
12/27/20	27,183	27,248
1/3/20	31,078	33,457
1/10/20	35,210	42,901
1/17/20	39,232	52,077
1/24/20	42,980	61,541
1/31/20	45,777	69,334
2/7/20	47,125	74,202
2/14/20	46,901	76,371
2/21/20	45,690	74,913
2/28/20	42,910	69,637
3/7/20	38,745	61,531

Weekly confirmed cases

## If Adaptive-LessControl scenario persists:

- All regions approach initial bed capacity this winter
- Surge capacity exceeded in Northern region, in mid-Jan to early March

\* Assumes average length of stay of 8 days

# Key Takeaways

Projecting future cases precisely is impossible and unnecessary.  
Even without perfect projections, we can confidently draw conclusions:

- **Case rate growth in Virginia slows and steadies with mixed patterns across commonwealth**
- VA mean weekly incidence (43/100K) steady (from 44) as national surge slows and is slightly down for first week in months (to 59/100K from 66/100K).
- Recent updates:
  - Preliminary estimates for vaccination impact
  - Planning scenarios remain on Christmas holiday, Dec 24<sup>th</sup>
- Behavioral changes can outpace impact of optimistic vaccine rollout and prevent significantly more cases by Spring
- The situation is changing rapidly. Models will be updated regularly

# References

Venkatramanan, S., et al. "Optimizing spatial allocation of seasonal influenza vaccine under temporal constraints." *PLoS computational biology* 15.9 (2019): e1007111.

Arindam Fadikar, Dave Higdon, Jiangzhuo Chen, Bryan Lewis, Srinivasan Venkatramanan, and Madhav Marathe. Calibrating a stochastic, agent-based model using quantile-based emulation. *SIAM/ASA Journal on Uncertainty Quantification*, 6(4):1685–1706, 2018.

Adiga, Aniruddha, Srinivasan Venkatramanan, Akhil Peddireddy, et al. "Evaluating the impact of international airline suspensions on COVID-19 direct importation risk." *medRxiv* (2020)

NSSAC. PatchSim: Code for simulating the metapopulation SEIR model. <https://github.com/NSSAC/PatchSim> (Accessed on 04/10/2020).

Virginia Department of Health. COVID-19 in Virginia. <http://www.vdh.virginia.gov/coronavirus/> (Accessed on 04/10/2020)

Biocomplexity Institute. COVID-19 Surveillance Dashboard. <https://nssac.bii.virginia.edu/covid-19/dashboard/>

Google. COVID-19 community mobility reports. <https://www.google.com/covid19/mobility/>

Biocomplexity page for data and other resources related to COVID-19: <https://covid19.biocomplexity.virginia.edu/>



# Questions?

## Points of Contact

Bryan Lewis

[brylew@virginia.edu](mailto:brylew@virginia.edu)

Srini Venkatramanan

[srini@virginia.edu](mailto:srini@virginia.edu)

Madhav Marathe

[marathe@virginia.edu](mailto:marathe@virginia.edu)

Chris Barrett

[ChrisBarrett@virginia.edu](mailto:ChrisBarrett@virginia.edu)

## Biocomplexity COVID-19 Response Team

Aniruddha Adiga, Abhijin Adiga, Hannah Baek, Chris Barrett, Golda Barrow, Richard Beckman, Parantapa Bhattacharya, Andrei Bura, Jiangzhuo Chen, Patrick Corbett, Clark Cucinell, Allan Dickerman, Stephen Eubank, Arindam Fadikar, Joshua Goldstein, Stefan Hoops, Ben Hurt, Sallie Keller, Ron Kenyon, Brian Klahn, Gizem Korkmaz, Vicki Lancaster, Bryan Lewis, Dustin Machi, Chunhong Mao, Achla Marathe, Madhav Marathe, Fanchao Meng, Henning Mortveit, Mark Orr, Joseph Outten, Akhil Peddireddy, Przemyslaw Porebski, SS Ravi, Erin Raymond, Jose Bayoan Santiago Calderon, James Schlitt, Aaron Schroeder, Stephanie Shipp, Samarth Swarup, Alex Telionis, Srinivasan Venkatramanan, Anil Vullikanti, James Walke, Amanda Wilson, Dawen Xie



UNIVERSITY OF VIRGINIA

BIOCOMPLEXITY INSTITUTE

# Supplemental Slides



---

BIOCOMPLEXITY INSTITUTE

# Estimating Daily Reproductive Number



Dec 11<sup>th</sup> Estimates

Region	Date of Onset	Date Onset Diff
	R <sub>e</sub>	Last Week
State-wide	0.977	-0.275
Central	0.854	-0.491
Eastern	1.009	-0.176
Far SW	1.083	-0.323
Near SW	0.988	-0.301
Northern	0.949	-0.253
Northwest	1.054	-0.193



## Methodology

- Wallinga-Teunis method (EpiEstim<sup>1</sup>) for cases by date of onset
- Serial interval: 6 days (2 day std dev)
- Recent estimates may be unstable due to backfill

1. Anne Cori, Neil M. Ferguson, Christophe Fraser, Simon Cauchemez. A New Framework and Software to Estimate Time-Varying Reproduction Numbers During Epidemics. American Journal of Epidemiology, Volume 178, Issue 9, 1 November 2013, Pages 1505–1512,  
<https://doi.org/10.1093/aje/kwt133>




# Mask usage sample sizes



# Agent-based Model (ABM)


## EpiHiper: Distributed network-based stochastic disease transmission simulations

- Assess the impact on transmission under different conditions
- Assess the impacts of contact tracing



### Synthetic Population

- Census derived age and household structure
- Time-Use survey driven activities at appropriate locations




### Detailed Disease Course of COVID-19

- Literature based probabilities of outcomes with appropriate delays
- Varying levels of infectiousness
- Hypothetical treatments for future developments

# ABM Social Distancing Rebound Study Design


## Study of "Stay Home" policy adherence

- Calibration to current state in epidemic
- Implement “release” of different proportions of people from “staying at home”



### Calibration to Current State

- Adjust transmission and adherence to current policies to current observations
- For Virginia, with same seeding approach as PatchSim



### Impacts on Reproductive number with release

- After release, spike in transmission driven by additional interactions at work, retail, and other
- At 25% release (70-80% remain compliant)
- Translates to 15% increase in transmission, which represents a 1/6<sup>th</sup> return to pre-pandemic levels

# Medical Resource Demand Dashboard

<https://nssac.bii.virginia.edu/covid-19/vmrddash/>

